Skip to main content
S. 252 115th Congress Senate

Medicare Drug Savings Act of 2017

Official title: A bill to amend title XVIII of the Social Security Act to require drug manufacturers to provide drug rebates for drugs dispensed to low-income individuals unde… Show full official titleShow less

Official title: A bill to amend title XVIII of the Social Security Act to require drug manufacturers to provide drug rebates for drugs dispensed to low-income individuals under the Medicare prescription drug benefit program.

Introduced: February 1, 2017 See on congress.gov
Health Government information and archivesHealth care costs and insuranceInflation and pricesMedicaid
More subjectsShow fewer subjects
MedicarePrescription drugsPublic contracts and procurementRetail and wholesale trades
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 1, 2017
Read twice and referred to the Committee on Finance.
Feb 1, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 1, 2017

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Medicare Drug Savings Act of 2017

This bill requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for prescription drugs dispensed to eligible low-income individuals under the Medicare prescription drug benefit or a Medicare Advantage (MA) prescription drug plan (PDP).

Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

 Related & companion bills 5
  • S 1511 Keeping Health Insurance Affordable Act of 2017
  • HR 1776 Improving Access To Affordable Prescription Drugs Act
  • S 771 Improving Access To Affordable Prescription Drugs Act
  • S 3411 Affordable Medications Act
  • HR 4138 Medicare Drug Price Negotiation Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 10
All 10 Democratic 8 Independent 2
D
Shaheen, Jeanne
New Hampshire · Mar 7, 2017
 D
Baldwin, Tammy
Wisconsin · Feb 1, 2017
 D
Blumenthal, Richard
Connecticut · Feb 1, 2017
 D
Durbin, Richard J.
Illinois · Feb 1, 2017
 D
Hirono, Mazie K.
Hawaii · Feb 1, 2017
 I
King, Angus S., Jr.
Maine · Feb 1, 2017
 D
Klobuchar, Amy
Minnesota · Feb 1, 2017
 D
Reed, Jack
Rhode Island · Feb 1, 2017
 I
Sanders, Bernard
Vermont · Feb 1, 2017
 D
Whitehouse, Sheldon
Rhode Island · Feb 1, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). S. 252: Medicare Drug Savings Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-S-252/
MLA
"S. 252: Medicare Drug Savings Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-252/.
Bluebook (legal)
S. 252, 115th Cong. (2026), https://openamerica.io/bill/115-S-252/.
Markdown link
[S. 252: Medicare Drug Savings Act of 2017](https://openamerica.io/bill/115-S-252/)
Report a problem